Valion Bio, Inc. (VBIO)
| Market Cap | 921.84K -73.3% |
| Revenue (ttm) | n/a |
| Net Income | -13.81M |
| EPS | -8.00 |
| Shares Out | 3.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 115,380 |
| Open | 0.2878 |
| Previous Close | 0.2854 |
| Day's Range | 0.2750 - 0.2996 |
| 52-Week Range | 0.2510 - 5.6000 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr... [Read more]
Financial Performance
Financial StatementsNews
Valion Bio’s regulatory dossier for Entolimod accepted for review in Ukraine
Valion Bio (VBIO) announced that Ukraine’s Ministry of Health, or MoH, has accepted the Company’s regulatory dossier for Entolimod for formal review under Ukraine’s Regulatory Equivalence Pathway, fol...
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days. Ukraine Ministry of ...
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio's Entolimod in cancer patients, creating a second clinical development pathway...
Valion Bio files to sell 29.41M shares of common stock, warrants
Dawson James Securities is acting as sole placement agent.
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
Valion Bio reports continued development of Entolimod program
Valion Bio (VBIO) reported across a series of strategic initiatives for its Entolimod program – including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndr...
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care SAN ANTONIO,...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company's lead candidate Positive momentum further positions Entolimod as a potential ...
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Emanates from the FY27 NDAA process underway in the U.S. Congress Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Com...
Valion Bio Transcript: AGM 2026
The meeting marked the first under the new company name and focused on executing a biopharma strategy. All eight shareholder proposals, including director election and share issuances, were approved, with strong emphasis on clinical development and governance.
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innat...
Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform
Valion Bio’s (VBIO) wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio for LarmorBio’s BioScan-NMR platform, a next-g...
Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year
Cash and cash equivalents at March 31, 2026 totaled $7.2M vs. $12.6M at December 31, 2025. The company continues to evaluate capital alternatives to support continued execution against pipeline, regul...
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics SAN ANTONIO, May 14,...
Valion Bio Earnings Call Transcript: Q1 2026
Rebranding and operational launch of Velocity Bioworks drove a significant increase in expenses and strategic progress, with government-funded programs de-risking entolimod's pathway. Near-term revenue is expected from biomanufacturing, while clinical and regulatory milestones are targeted for late 2026.
Valion Bio Earnings release: Q1 2026
Valion Bio released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Valion Bio Quarterly report: Q1 2026
Valion Bio has published its Q1 2026 quarterly earnings report on May 14, 2026.
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks Conference Call to be Hel...
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radi...
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
Senator John Cornyn recognizes facility's role in advancing radiation countermeasures for cancer patients and U.S. warfighters; Mayor Gina Ortiz Jones, Office of Senator Cornyn, and Velocity Bioworks ...
Valion Bio receives first study protocol under agreement with NIAID
Valion Bio (VBIO) announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases, a ...
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure Has ...
Valion Bio names Melinda Lackey as General Counsel
Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experienc...